Literature DB >> 9620717

Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy.

C H Gonzalez1, M J Marques-Dias, C A Kim, S M Sugayama, J A Da Paz, S M Huson, L B Holmes.   

Abstract

BACKGROUND: Misoprostol is commonly used to induce abortion in Brazil, and in other countries in South and Central America where abortions are illegal. However, misoprostol is not very effective in inducing abortions, and exposure to the drug in utero can cause abnormalities in the fetus. We aimed to define the common phenotypical effects of exposure to the drug.
METHODS: We studied 42 infants from São Paulo, Brazil, who were exposed to misoprostol during the first 3 months of gestation, and then born with congenital abnormalities. We interviewed each of the infants' mothers to find out about misoprostol exposure and dosage. Each infant was physically examined by a geneticist or a neuropaediatrician.
FINDINGS: 17 of the infants had equinovarus with cranial-nerve defects. Ten children had equinovarus as part of more extensive arthrogryposis. The most distinctive phenotypes were arthrogryposis confined to the legs (five cases) and terminal transverse-limb defects (nine cases) with or without Mobius sequence. The most common dose of misoprostol taken was 800 microg (range 200-16000 microg).
INTERPRETATION: Deformities attributed to vascular disruption were found in these children. We suggest that the uterine contractions induced by misoprostol cause vascular disruption in the fetus, including brain-stem ischaemia. Information on the effects of taking misoprostol during pregnancy should be made more widely available, to dissuade women from misusing the drug.

Entities:  

Keywords:  Abortifacient Agents--side effects; Abortion Failure; Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Brazil; Case Studies; Congenital Abnormalities; Developing Countries; Diseases; Endocrine System; Family Planning; Fertility Control, Postconception; Fetus; Latin America; Misoprostol--side effects; Neonatal Diseases And Abnormalities; Physiology; Pregnancy; Pregnancy, First Trimester; Prostaglandins; Prostaglandins, Synthetic; Reproduction; Research Methodology; Research Report; South America; Studies

Mesh:

Substances:

Year:  1998        PMID: 9620717     DOI: 10.1016/S0140-6736(97)12363-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world.

Authors:  Rohini B M Fernandopulle; Krisantha Weerasuriya
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Medical genetics: 1. Clinical teratology in the age of genomics.

Authors:  Janine E Polifka; J M Friedman
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

Review 3.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

4.  Reproductive results associated with misoprostol and other substances utilized for interruption of pregnancy.

Authors:  Tatiane da Silva Dal Pizzol; Vera Lúcia Tierling; Lavinia Schüler-Faccin; Maria Teresa Vieira Sanseverino; Sotero Serrate Mengue
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

5.  Moebius-Poland syndrome and drug associations.

Authors:  Simon William Dubrey; Maneesh C Patel; Omar Malik
Journal:  BMJ Case Rep       Date:  2009-04-07

Review 6.  What can we learn from the thalidomide experience: an ophthalmologic perspective.

Authors:  Marilyn T Miller; Kerstin K Strömland
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

7.  Termination of Pregnancy in First Trimester - Medical Option.

Authors:  Sushil Kumar; Z K Antony; A Kapur; M Togra
Journal:  Med J Armed Forces India       Date:  2011-07-21

8.  Risk classification systems for drug use during pregnancy: are they a reliable source of information?

Authors:  A Addis; S Sharabi; M Bonati
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

9.  Autism with ophthalmologic malformations: the plot thickens.

Authors:  Marilyn T Miller; Kerstin Strömland; Liana Ventura; Maria Johansson; Jose M Bandim; Christopher Gillberg
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 10.  A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

Authors:  Deborah A Wing
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.